These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37796134)

  • 21. Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial--rationale and design.
    Sakata Y; Nochioka K; Miura M; Takada T; Tadaki S; Miyata S; Shiba N; Shimokawa H
    J Cardiol; 2013 Jul; 62(1):31-6. PubMed ID: 23769179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.
    Zaiken K; Hudd TR; Cheng JW
    Ann Pharmacother; 2013 May; 47(5):686-93. PubMed ID: 23585649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
    Zannad F; Fay R
    Fundam Clin Pharmacol; 2007 Apr; 21(2):181-90. PubMed ID: 17391291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of proteinuria with angiotensin receptor blockers.
    Galle J
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin II receptor blockers for the treatment of hypertension.
    See S
    Expert Opin Pharmacother; 2001 Nov; 2(11):1795-804. PubMed ID: 11825317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study.
    Eworuke E; Shinde M; Hou L; Paterson MJ; Jensen PB; Maro JC; Rai A; Scarnecchia D; Pennap D; Woronow D; Ghosh RE; Welburn S; Pottegard A; Platt RW; Lee H; Bradley MC
    BMJ Open; 2023 Apr; 13(4):e070985. PubMed ID: 37068898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants.
    Mason RP; Jacob RF; Kubant R; Jacoby A; Louka F; Corbalan JJ; Malinski T
    Br J Clin Pharmacol; 2012 Jul; 74(1):141-6. PubMed ID: 22283728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
    Hasegawa H; Takano H; Kameda Y; Kubota A; Kobayashi Y; Komuro I
    Clin Exp Hypertens; 2012; 34(2):86-91. PubMed ID: 22251314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
    Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
    Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
    Ball SG; White WB
    Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
    Antoniou T; Camacho X; Yao Z; Gomes T; Juurlink DN; Mamdani MM
    CMAJ; 2013 Sep; 185(12):1035-41. PubMed ID: 23836857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements.
    Satoh M; Haga T; Hosaka M; Obara T; Metoki H; Murakami T; Kikuya M; Inoue R; Asayama K; Mano N; Ohkubo T; Imai Y
    J Hypertens; 2016 Jun; 34(6):1218-23. PubMed ID: 27027425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic potential of angiotensin receptor blockers in hypertension.
    Cheung BM
    Expert Opin Investig Drugs; 2006 Jun; 15(6):625-35. PubMed ID: 16732715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
    Ram CV; Ramaswamy K; Qian C; Biskupiak J; Ryan A; Quah R; Russo PA
    J Clin Hypertens (Greenwich); 2011 Nov; 13(11):801-12. PubMed ID: 22051424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.
    Harada N; Shimozawa N; Okajima K
    Transl Res; 2009 Sep; 154(3):142-52. PubMed ID: 19665690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
    Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
    J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect.
    Meredith PA
    Am J Cardiovasc Drugs; 2005; 5(3):171-83. PubMed ID: 15901205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
    Yoo YG; Lim MJ; Kim JS; Jeong HE; Ko H; Shin JY
    Medicine (Baltimore); 2023 Nov; 102(46):e36098. PubMed ID: 37986329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.